Regions Financial Corp Supernus Pharmaceuticals, Inc. Transaction History

Regions Financial Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 29, 2020	SELL	$14.45 - $24.69 $137,433 - $234,826	-9,511 Closed	0 $0
Q4 2019 Feb 03, 2020	BUY	$19.93 - $29.13 $2,511 - $3,670	126 Added 1.34%	9,511 $226,000
Q3 2019 Oct 24, 2019	SELL	$25.47 - $33.37 $15,485 - $20,288	-608 Reduced 6.08%	9,385 $258,000
Q2 2019 Jul 19, 2019	SELL	$29.96 - $38.87 $16,927 - $21,961	-565 Reduced 5.35%	9,993 $330,000
Q1 2019 Apr 19, 2019	BUY	$32.77 - $41.99 $29,263 - $37,497	893 Added 9.24%	10,558 $370,000
Q4 2018 Jan 28, 2019	BUY	$30.84 - $49.51 $73,615 - $118,180	2,387 Added 32.8%	9,665 $321,000
Q3 2018 Oct 22, 2018	BUY	$42.7 - $56.55 $92,957 - $123,109	2,177 Added 42.68%	7,278 $366,000
Q2 2018 Jul 26, 2018	SELL	$44.1 - $59.85 $30,561 - $41,476	-693 Reduced 11.96%	5,101 $306,000
Q1 2018 Apr 18, 2018	SELL	$37.15 - $46.9 $46,994 - $59,328	-1,265 Reduced 17.92%	5,794 $266,000
Q4 2017 Jan 18, 2018	SELL	$36.4 - $42.6 $197,688 - $231,360	-5,431 Reduced 43.48%	7,059 $281,000
Q3 2017 Oct 23, 2017	BUY	$36.75 - $49.65 $459,007 - $620,128	12,490	12,490 $500,000

302

60.7M

22.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.73B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Regions Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Regions Financial Corp with notifications on news.